Elegen Videos

Matthew Hill, founder and CEO of Elegen joins a Drug Discovery World webinar to discuss the DNA supply bottleneck in mRNA drug development workflows and how Elegen uses an innovative approach to DNA synthesis to supply biopharma companies rapidly and reliably with long, accurate, dsDNA. With ENFINIA DNA, scientists can eliminate several steps of the traditional mRNA therapy screening and production processes to bring new therapies to market faster.

Evolution of DNA Supply, What Advances in DNA Synthesis will Unlock the Agile Development of Biology.

Chris Ghadban, Principal of Alix Ventures, moderates a panel of guests including Matthew Hill, Founder and CEO of Elegen, Jacob Becraft, Co-Founder and CEO of Strand Therapeutics, Tim Lu, Co-founder and CEO of Senti Bio, Cristina Butterfield, Sr. Director of Biochemistry at Metagenomi, and Patrick Boyle, Organism Designer at Ginkgo Bioworks, to discuss how a better solution for DNA synthesis will enable synthetic biologists to realize the promise of programmable biology.

Recorded at the BIO2023 International Convention, Julianna LeMieux, Deputy Editor and Chief of Genetic Engineering News moderates this discussion about the impacts and future of DNA synthesis and synthetic biology with industry thought leaders Matthew Hill, Founder and CEO of Elegen, Madoo Varma, VP of Business Development at DNA Script, Elaine Shapland, Sr. Director of Build Technology Development at Ginkgo Bioworks, and Daniel Arlo, CEO of Ansa.

Update on the latest advancements of Elegen's products and technology, presented at the Synbiobeta 2023 conference, by Matthew Hill, Founder and CEO.